The purpose of this study is to evaluate the safety and efficacy of the GTS400 trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.

Glaucoma is a collection of disorders characterized by progressive loss of visual field due to optic nerve damage. It is a leading cause of blindness in the United States, affecting 1-2% of individuals aged 60 and over. Management of glaucoma requires chronic, life-long treatment with a spectrum of therapeutic options including medications, laser treatment and surgical implants. The common goal among the various therapies is to lower intraocular pressure to target levels in order to prevent loss of visual fields from excessive pressure on the optic nerve.

Inclusion Criteria:

• Diagnosed with open-angle glaucoma in the study eye
• Subject must be on 1 to 3 glaucoma medications
• Subject able and willing to attend follow up visits for two years postop
• Subject able and willing to sign informed consent

Exclusion Criteria:

• Pseudoexfoliative and pigmentary glaucoma
• Prior glaucoma surgery of any type